Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Cytokinetics falls on omecamtiv mecarbil data

Cytokinetics Inc. (NASDAQ:CYTK) fell $2.82 (27%) to $7.65 on Tuesday after it and partner Amgen Inc. (NASDAQ:AMGN) said

Read the full 184 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE